Accessibility Menu
Evelo Biosciences logo

Evelo Biosciences(OTC) EVLO

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-100%
1 Month+0%
$0.00
+0.00%
+0.00Today
Evelo Biosciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-20
Evelo Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99%USD 0.002026-08-07
1 month+0%USD 0.002026-07-17
3 month-99%USD 0.002026-05-22
Year to date-99.8%USD 0.002025-12-31
1 year-99.8%USD 0.002025-08-20
3 year-100%USD 6.942023-08-21
5 year-100%USD 188.402021-08-20
Since inception-100%USD 325.002018-05-09

Evelo Biosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$82.35M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-51.48 (Low)

Price

$0.00

Volume

1

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 24, 2026

EVLO News

493 gut microbiome

Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.

Maxx ChatskoSep 17, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evelo Biosciences

Evelo Biosciences, Inc. is a biotechnology firm focused on developing oral biologic therapies for inflammatory conditions and oncological diseases. The company is advancing a diverse pipeline of drug candidates, including EDP1815, EDP1867, EDP2939, and EDP1908, targeting various health challenges.

Products and Services
  • EDP1815: A whole-microbe compound in Phase 2 trials for psoriasis and atopic dermatitis
  • EDP1867: An inactivated oral biologic in Phase 1b for inflammatory diseases
  • EDP1908: A drug candidate aimed at treating cancer
Growth Outlook
  • Ongoing Phase 2 trials for EDP1815 may lead to significant market opportunities
  • Expansion of the pipeline with EDP1867 and EDP2939 enhances potential revenue streams
  • Focus on oral biologics aligns with increasing demand for non-invasive therapies
Financial Highlights
  • Q3 2023 net income of -$12.36 million, reflecting ongoing investment in R&D
  • Cash and cash equivalents of $17.26 million as of September 30, 2023
  • Current ratio of 4.16 indicates strong liquidity position
Evelo Biosciences, Inc. operates in a promising sector with a focus on innovative therapies. The company's commitment to advancing its pipeline could position it favorably in the biotechnology landscape. Recent financial data shows a significant investment in research and development, which is essential for long-term growth. The liquidity position remains strong, providing a buffer for ongoing operations and development efforts. As the company continues to progress through clinical trials, it may attract attention from investors looking for opportunities in the biotechnology field.
AI Generated • Jul 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

66

CEO

Simba Gill, PhD, MBA

Website

www.evelobio.com

Headquarters

Cambridge, MA 02139, US

EVLO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-6232.76%

Return on Capital

-235.05%

Return on Assets

-177.72%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.98M

Volume

1

Avg. Volume

350.603

Financials (TTM)

Gross Profit

-$2.41M

Operating Income

-$76.74M

EBITDA

-$74.40M

Operating Cash Flow

-$73.70M

Capital Expenditure

-$287.00K

Free Cash Flow

-$73.99M

Cash & ST Invst.

$17.26M

Total Debt

$33.95M

Evelo Biosciences Performance Analysis

Evelo Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
Evelo Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Evelo Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -46.18N/A
20222022-12-31USD -26.28-43.1%
Evelo Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-3124.2%
Q12023-03-31-6.5%
Q22023-06-3017.3%
Q32023-09-30-1781.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$793.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

66

N/A

Net Income

-$12.36M

+59.5%

EBITDA

-$11.05M

+62.0%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$17.26M

-75.0%

Total Debt

$33.95M

-38.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$33.95M

+135.0%

Return on Assets

-1.78%

N/A

Return on Invested Capital

-2.08%

N/A

Free Cash Flow

-$10.46M

+53.7%

Operating Cash Flow

-$10.41M

+53.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INFIQInfinity Pharmaceuticals, Inc.
$0.00+0.00%
LIFSLife Stem Genetics Inc.
$0.00+0.00%
ARDSAridis Pharmaceuticals, Inc.
$0.00+0.00%
STABStatera Biopharma, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About EVLO

What is the current price of Evelo Biosciences?

Evelo Biosciences is trading at $0.00 per share.

What is the 52-week range for Evelo Biosciences?

Over the past 52 weeks, Evelo Biosciences has traded between $0.00 and $0.00.

How much debt does Evelo Biosciences have?

As of the most recent reporting period, Evelo Biosciences reported total debt of $51.14M.

How much cash does Evelo Biosciences have on hand?

Evelo Biosciences reported $47.94M in cash and cash equivalents in its most recent financial results.

What is Evelo Biosciences’s dividend yield?

Evelo Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services